Special Issue "Therapeutic Use of Phytopharmaceuticals in Non-communicable Diseases"
Deadline for manuscript submissions: 31 January 2022.
Interests: noncommunicable diseases; clinical and preclinical studies; real world evidence; patient reported outcomes; biomolecular research; cellular biology; plant derived bioactives; phytopharmaceuticals; biomarkers
Special Issues and Collections in MDPI journals
Noncommunicable diseases (NCDs) account for 41 million deaths annually. This is equivalent to 71% of all deaths globally. Among NCD deaths, cardiovascular diseases are the most frequent (17.9 million people annually), followed by cancers (9.3 million), respiratory diseases (4.1 million), and diabetes (1.5 million). According to WHO reports, these four groups of diseases account for over 80% of all premature NCD deaths.
The top risks for dying from a NCD are tobacco use, physical inactivity, the harmful use of alcohol, and unhealthy diets. NCDs result from a combination of genetic, physiological, environmental, and behavioral factors. The exorbitant costs of NCDs, including treatment, which is often lengthy and expensive, have a high socioeconomic impact.
Many patients suffering from NCDs bear more than one disease contemporarily. This multimorbidity is often treated by more than 5 drugs, which leads to undesired side effects from multimedication. Quality of life can be severely impaired, leading to a demand for novel therapy strategies, including drugs with fewer side-effects. In this context, plant-derived drugs may play an important role. In recent decades, preclinical research has revealed the potential of plant-derived bioactives to modulate molecular and cellular pathways associated with NCDs. However, for the use of plant-derived drugs in the clinical setting, evidence has to be provided. Therefore, clinical studies are necessary to transfer the knowledge gained from in vitro and in vivo experiments into clinical practice.
Natural plant-derived compounds have one significant advantage: They largely do not exert side effects. This feature qualifies them not only for therapeutic use but also for primary prevention, in healthy persons with a predisposition to NCDs, e.g., cancer, arteriosclerosis or chronic inflammatory diseases. However, toxic effects, especially concerning high dosages, long-term intake, and pharmacological interactions with other compounds, have to be tested.
This Special Issue is open to any report regarding studies on plant derived drugs and bioactives for the use in NCDs. The objective is to collect evidence for the use of plant-derived drugs in the prevention and clinical setting of NCDs.
Importantly, the exact active ingredient of a plant extract must be reported in the submitted research manuscript, since papers describing effects of mixed extraction from plants will not be accepted.
Prof. Dr. Beatrice E. Bachmeier
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- noncommunicable diseases
- clinical and preclinical studies
- real-world evidence
- patient-reported outcomes
- biomolecular research
- cellular biology
- plant-derived bioactives